Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Mondelez Likely to Post In-Line Q3 Revenue, Slightly Below-Consensus EPS, RBC Capital Markets Says

Mondelez Likely to Post In-Line Q3 Revenue, Slightly Below-Consensus EPS, RBC Capital Markets Says

MT newswireMT newswire2026/10/26 15:06
11:06 AM EDT, 10/26/2026 (MT Newswires) -- Mondelez International (MDLZ) is likely to report Q3 revenue in line with consensus estimates, but earnings per share may come in slightly below market expectations, RBC Capital Markets said in a note Monday. Recent comments by management and channel checks are supportive of the business despite some lingering headwinds, the investment firm said, adding it continues to view management's full-year guidance as achievable. RBC said the "real opportunity" is for the company to replicate its Oreos model with its other brands. North America channel trends are slightly softer, with sales growth in tracked channels up 1.1% in Q3, slower than the 2% growth in the previous quarter, while in Europe, the company is performing as expected, RBC said. Mondelez is set to report its Q3 financial results on Thursday. RBC Capital Markets has an outperform rating on Mondelez and a $66 price target. Price: 62.98, Change: -0.82, Percent Change: -1.29
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test